Cargando…

Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model

BACKGROUND: The treatment paradigm in advanced renal cell carcinoma (RCC) has changed in the recent years. Sunitinib has been established as a new standard for first-line therapy. We studied the prognostic significance of baseline characteristics and we compared the risk stratification with the esta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bamias, Aristotelis, Karadimou, Alexandra, Lampaki, Sofia, Lainakis, George, Malettou, Lia, Timotheadou, Eleni, Papazisis, Kostas, Andreadis, Charalambos, Kontovinis, Loukas, Anastasiou, Ioannis, Stravodimos, Kostas, Xanthakis, Ioannis, Skolarikos, Andreas, Christodoulou, Christos, Syrigos, Kostas, Papandreou, Christos, Razi, Evangelia, Dafni, Urania, Fountzilas, George, Dimopoulos, Meletios A
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837011/ https://www.ncbi.nlm.nih.gov/pubmed/20163744 http://dx.doi.org/10.1186/1471-2407-10-45

Ejemplares similares

The Memorial Sloan Kettering Prognostic Score: Correlation with survival in patients with advanced gastric cancer
por: Wan, Mingyu, et al.
Publicado: (2023)

Caregivers Clinic at Memorial Sloan Kettering Cancer Center
por: Applebaum, Allison
Publicado: (2021)

Surgical management of hilar cholangiocarcinoma at Memorial Sloan Kettering Cancer Center
por: Lidsky, Michael E., et al.
Publicado: (2018)

Integrative Cancer Care in a US Academic Cancer Centre: The Memorial Sloan–Kettering Experience
por: Deng, G.
Publicado: (2008)

Memorial Sloan-Kettering Cancer Center: Two Decades of Experience with Ductal Carcinoma In Situ of the Breast
por: Choi, Daniel Xavier, et al.
Publicado: (2012)

Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience
por: Bazzi, Wassim M., et al.
Publicado: (2014)

Rivaroxaban treatment of cancer‐associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience
por: Soff, Gerald A., et al.
Publicado: (2019)

The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma
por: Stofas, Anastasios, et al.
Publicado: (2014)

Evaluation of Memorial Sloan‐Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict Overall Survival in intracranial Primary CNS lymphoma
por: Jahr, Guro, et al.
Publicado: (2018)

Nasal metastases from renal cell carcinoma are associated with Memorial Sloan-Kettering Cancer Center poor-prognosis classification
por: Choong, Caroline Victoria, et al.
Publicado: (2011)

Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience
por: Rubinstein, Maria, et al.
Publicado: (2019)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
por: Tzeng, Michael, et al.
Publicado: (2021)

Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram
por: Oses, Gabriela, et al.
Publicado: (2023)

Antiproliferative Effects of the Methanolic Petiole Extract of Eichhornia crassipes Against Sloan Kettering Melanoma 5 Cell Line: An In Vitro Study
por: P, Noufal K, et al.
Publicado: (2022)

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials
por: Fountzilas, George, et al.
Publicado: (2013)

Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma
por: Papazisis, Konstantinos T, et al.
Publicado: (2010)

The difference in the survival rate of patients with metastatic renal cell carcinoma in the intermediate-risk group of the Memorial Sloan Kettering Cancer Center criteria
por: Tamada, Satoshi, et al.
Publicado: (2018)

The association between Memorial Sloan Kettering Frailty Index with 30-day survival among patients aged ≥ 75 with cancer and COVID-19
por: Kim, Soo Jung, et al.
Publicado: (2022)

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis
por: Pectasides, Dimitrios, et al.
Publicado: (2012)

Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
por: Fountzilas, George, et al.
Publicado: (2014)

Thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis (FAP): Memorial Sloan-Kettering Cancer Center (MSKCC) registry experience
por: Markowitz, Arnold J, et al.
Publicado: (2011)

Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience
por: Page, David B, et al.
Publicado: (2014)

Management of Locally Advanced Rectal Cancer During The COVID-19 Pandemic: A Necessary Paradigm Change at Memorial Sloan Kettering Cancer Center
por: Romesser, Paul B., et al.
Publicado: (2020)

External validation of Memorial Sloan Kettering Cancer Center nomogram and prediction of optimal candidate for lymph node dissection in clinically localized prostate cancer
por: Milonas, Daimantas, et al.
Publicado: (2020)

MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system
por: Kim, Sehui, et al.
Publicado: (2016)

Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration
por: Bamias, A, et al.
Publicado: (2013)

Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer
por: Fountzilas, Elena, et al.
Publicado: (2018)

Validation of the Memorial Sloan-Kettering Cancer Center Nomogram to Predict Disease-Specific Survival after R0 Resection in a Chinese Gastric Cancer Population
por: Chen, Donglai, et al.
Publicado: (2013)

Validation of the Memorial Sloan Kettering Cancer Center nomogram for predicting non-sentinel lymph node metastasis in sentinel lymph node-positive breast-cancer patients
por: Bi, Xiang, et al.
Publicado: (2015)

The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking
por: Tsantikidi, Aikaterini, et al.
Publicado: (2023)

Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
por: Fountzilas, George, et al.
Publicado: (2012)

Late-Onset Cervical Pseudomeningocele Following Ossification of the Posterior Longitudinal Ligament Surgery Successfully Treated With a Lumboperitoneal Shunt
por: Tzerefos, Christos, et al.
Publicado: (2022)

Impact of the Discordance Between Scales of Memorial Sloan-Kettering Cancer Center and International Metastatic Renal Cell Carcinoma Database Consortium in Patients’ Prognosis With Metastatic Renal Cancer
por: Grimaldo-Roque, Hiram Josue, et al.
Publicado: (2022)

Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma: Model development and external validation with Memorial Sloan Kettering Cancer Center model and the international metastatic renal cell carcinoma database consortium model
por: Shin, Dongrul, et al.
Publicado: (2021)

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
por: Kontovinis, Loukas F, et al.
Publicado: (2009)

Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer
por: Fountzilas, Elena, et al.
Publicado: (2019)

A Comparison of Prognostic Value of the Levels of ProBNP and Troponin T in Patients with Acute Coronary Syndrome (ACS)
por: Vogiatzis, Ioannis, et al.
Publicado: (2016)

In what extent anemia coexists with cognitive impairment in elderly: a cross-sectional study in Greece
por: Argyriadou, Stella, et al.
Publicado: (2001)

Outcome of patients with nonmetastatic muscle‐invasive bladder cancer not undergoing cystectomy after treatment with noncisplatin‐based chemotherapy and/or radiotherapy: a retrospective analysis
por: Bamias, Aristotle, et al.
Publicado: (2016)

PB.3. Detection of lymph node metastases in newly diagnosed breast cancer patients with axillary ultrasonography in combination with the Memorial Sloan Kettering Cancer Centre normogram as a prediction tool
por: Low, CS, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9ljtc3uki8jsogll2vff8fjjoj